RUNX1 and prostate carcinoma: Taken together, HA has an efficacy to suppress the migratory and invasion potential of prostate cancer PC3 and LNCaP cells as well as overexpressing RUNX1 in PC3 cells via the downregulation of MMP2 and MMP9.